Vita 34 steht für Transparenz: Für unseren Elternratgeber führen wir deswegen hier alle Quellen und Referenzen auf.
Elternratgeber, Stand Mai 2021:
1. Galieva L.R;Mukhamedshina Y.O;Arkhipova S.S., et al. Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. Front Pharmacol. 2017;8:628. doi:10.3389/fphar.2017.00628.
2. Sieburg H.B;Cattarossi G;Muller-Sieburg C.E. Lifespan differences in hematopoietic stem cells are due to imperfect repair and unstable mean-reversion. PLoS Comput Biol. 2013;9(4):e1003006. doi:10.1371/journal.pcbi.1003006.
3. Pillay J;den Braber I;Vrisekoop N., et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood. 2010;116(4):625-627. doi:10.1182/blood-2010-01-259028.
4. Park Y.M;Bochner B.S. Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res. 2010;2(2):87-101. doi:10.4168/aair.2010.2.2.87.
5. Siracusa M.C;Comeau M.R;Artis D. New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. Ann N Y Acad Sci. 2011;1217:166-177. doi:10.1111/j.1749-6632.2010.05918.x.
6. Patel A.A;Zhang Y;Fullerton J.N., et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J Exp Med. 2017;214(7):1913-1923. doi:10.1084/jem.20170355.
7. Kaestner L;Bogdanova A. Regulation of red cell life-span, erythropoiesis, senescence, and clearance. Front Physiol. 2014;5:269. doi:10.3389/fphys.2014.00269.
8. Franco R.S. Measurement of red cell lifespan and aging. Transfus Med Hemother. 2012;39(5):302-307. doi:10.1159/000342232.
9. Seifert M;Küppers R. Human memory B cells. Leukemia. 2016;30(12):2283-2292. doi:10.1038/leu.2016.226.
10. Dalous J;Larghero J;Baud O. Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives. Pediatr Res. 2012;71(4 Pt 2):482-490. doi:10.1038/pr.2011.67.
11. Willing A.E;Eve D.J;Sanberg P.R. Umbilical cord blood transfusions for prevention of progressive brain injury and induction of neural recovery: an immunological perspective. Regen Med. 2007;2(4):457-464. doi:10.2217/174607184.108.40.2067.
12. Saha A;Patel S;Xu L., et al. Human umbilical cord blood monocytes, but not adult blood monocytes, rescue brain cells from hypoxic-ischemic injury: Mechanistic and therapeutic implications. PLoS ONE. 2019;14(9):e0218906. doi:10.1371/journal.pone.0218906.
13. Davies J.E;Walker J.T;Keating A. Concise Review: Wharton’s Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. Stem Cells Transl Med. 2017;6(7):1620-1630. doi:10.1002/sctm.16-0492.
14. Arutyunyan I;Elchaninov A;Makarov A., et al. Umbilical Cord as Prospective Source for Mesenchymal Stem Cell-Based Therapy. Stem Cells Int. 2016;2016:6901286. doi:10.1155/2016/6901286.
15. AWMF. Leitlinie der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG): Betreuung von gesunden reifen Neugeborenen in der Geburtsklinik. 2012. https://www.awmf.org/uploads/tx_szleitlinien/024-005l_S2k_Betreuung_von_gesunden_reifen_Neugeborenen_2012-10-abgelaufen.pdf. Accessed January 8, 2020.
16. Committee Opinion No. 684: Delayed Umbilical Cord Clamping After Birth. Obstet Gynecol. 2017;129(1):e5-e10. doi:10.1097/AOG.0000000000001860.
17. Ciubotariu R;Scaradavou A;Ciubotariu I., et al. Impact of delayed umbilical cord clamping on public cord blood donations: can we help future patients and benefit infant donors? Transfusion. 2018;58(6):1427-1433. doi:10.1111/trf.14574.
18. Frändberg S;Waldner B;Konar J., et al. High quality cord blood banking is feasible with delayed clamping practices. The eight-year experience and current status of the national Swedish Cord Blood Bank. Cell Tissue Bank. 2016;17(3):439-448. doi:10.1007/s10561-016-9565-6.
19. Broxmeyer H.E. StemBook: Cord blood hematopoietic stem cell transplantation∗. Cambridge (MA); 2008. https://www.ncbi.nlm.nih.gov/books/NBK44751/. Accessed April 29, 2019.
20. Bönig H;Heiden M;Schüttrumpf J., et al. Potenzial hämatopoetischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige Therapien. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011;54(7):791-796. doi:10.1007/s00103-011-1305-2.
21. Mayani H;Wagner J.E;Broxmeyer H.E. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transplant. 2019. doi:10.1038/s41409-019-0546-9.
22. Dessels C;Alessandrini M;Pepper M.S. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. Stem Cells Transl Med. 2018;7(9):643-650. doi:10.1002/sctm.17-0244.
23. Ballen K. Update on umbilical cord blood transplantation. F1000Res. 2017;6:1556. doi:10.12688/f1000research.11952.1.
24. ClinicalTrials.gov. NCT03913312: Multicenter, One-arm, Phase II Clinical Study of Decitabine Combined With Unrelated Cord Blood Transplantation for the Treatment of Acute Myeloid Leukemia (AML) in the Elderly. https://clinicaltrials.gov/ct2/show/NCT03913312. Accessed December 7, 2020.
25. ClinicalTrials.gov. NCT03441958: A Phase I-II Open-label Study of Non-myeloablative-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT03441958. Accessed December 7, 2020.
26. ClinicalTrials.gov. NCT01451502: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units. https://clinicaltrials.gov/ct2/show/NCT01451502. Accessed December 7, 2020.
27. ClinicalTrials.gov. NCT02745717: The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia. https://clinicaltrials.gov/ct2/show/NCT02745717. Accessed December 7, 2020.
28. ClinicalTrials.gov. NCT03881774: Clinical Study of Cord Blood Derived CAR-T Cells in Patients With Refractory/Relapsed B Cell Leukemia/Lymphoma Who Are Failed for Autologous CAR-T Cells or Autologous CAR-T Can Not be Prepared. https://clinicaltrials.gov/ct2/show/NCT03881774?term=%22cord+blood%22%2C+%22CAR+T%22&rank=1. Accessed December 7, 2020.
29. ClinicalTrials.gov. NCT01861093: A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients. https://clinicaltrials.gov/ct2/show/NCT01861093. Accessed December 7, 2020.
30. ClinicalTrials.gov. NCT01768845: Unrelated Umbilical Cord Blood (UBC)Transplantation. https://clinicaltrials.gov/ct2/show/NCT01768845. Accessed December 7, 2020.
31. ClinicalTrials.gov. NCT01247701: Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML). https://clinicaltrials.gov/ct2/show/NCT01247701. Accessed December 7, 2020.
32. ClinicalTrials.gov. NCT00739141: A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. https://clinicaltrials.gov/ct2/show/NCT00739141. Accessed December 7, 2020.
33. ClinicalTrials.gov. NCT01553461: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications. https://clinicaltrials.gov/ct2/show/NCT01553461. Accessed December 7, 2020.
34. ClinicalTrials.gov. NCT02730299: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies. https://clinicaltrials.gov/ct2/show/NCT02730299. Accessed December 7, 2020.
35. ClinicalTrials.gov. NCT01962636: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases. https://clinicaltrials.gov/ct2/show/NCT01962636. Accessed December 7, 2020.
36. ClinicalTrials.gov. NCT03096782: Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment. https://clinicaltrials.gov/ct2/show/NCT03096782. Accessed December 7, 2020.
37. ClinicalTrials.gov. NCT01619761: Natural Killer Cells in Allogeneic Cord Blood Transplantation. https://clinicaltrials.gov/ct2/show/NCT01619761. Accessed December 7, 2020.
38. ClinicalTrials.gov. NCT02727803: Personalized NK Cell Therapy in Cord Blood Transplantation. https://clinicaltrials.gov/ct2/show/NCT02727803. Accessed December 7, 2020.
39. ClinicalTrials.gov. NCT01729091: Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT01729091. Accessed December 7, 2020.
40. ClinicalTrials.gov. NCT02280525: A Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Lymphodepleting Chemotherapy and Lenalidomide as Immunotherapy in Patients With Hematologic Malignancies. https://clinicaltrials.gov/ct2/show/NCT02280525. Accessed December 7, 2020.
41. ClinicalTrials.gov. NCT03056339: Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid Malignancies. https://clinicaltrials.gov/ct2/show/NCT03056339?term=%22cord+blood%22%2C+CAR%2C+NK&rank=1. Accessed June 18, 2019.
42. ClinicalTrials.gov. NCT03420963: Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults. https://clinicaltrials.gov/ct2/show/NCT03420963. Accessed December 7, 2020.
43. ClinicalTrials.gov. NCT03735277: Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke. https://clinicaltrials.gov/ct2/show/NCT03735277. Accessed June 21, 2019.
44. ClinicalTrials.gov. NCT02433509: Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke. https://clinicaltrials.gov/ct2/show/NCT02433509. Accessed June 21, 2019.
45. ClinicalTrials.gov. NCT01673932: Phase 1 Clinical Trial to Establish the Safety and Feasibility of Transplants of Umbilical Cord Blood Mononuclear Cells in Chronic Ischemic Stroke. https://clinicaltrials.gov/ct2/show/NCT01673932. Accessed June 21, 2019.
46. ClinicalTrials.gov. NCT03791372: Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy. https://clinicaltrials.gov/ct2/show/NCT03791372. Accessed December 7, 2020.
47. ClinicalTrials.gov. NCT02551003: A Multi-Centre Safety and Efficacy Study of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonates Encephalopathy in China. https://clinicaltrials.gov/ct2/show/NCT02551003. Accessed December 7, 2020.
48. ClinicalTrials.gov. NCT03696745: The Treatment of Premature Infants With Brain Injury by Autologous Umbilical Cord Blood Stem Cells. https://clinicaltrials.gov/ct2/show/NCT03696745. Accessed December 7, 2020.
49. ClinicalTrials.gov. NCT02952716: Treatment of Human Cord Blood Mononuclear Cell for Delayed Encephalopathy After Carbon Monoxide Poisoning. https://clinicaltrials.gov/ct2/show/NCT02952716. Accessed June 21, 2019.
50. ClinicalTrials.gov. NCT03352310: Umbilical Cord Blood Mononuclear Cell Bank in Hong Kong and Treatment of Neonatal Cerebral Ischemia and Anemia – Part IV Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT03352310. Accessed December 7, 2020.
51. ClinicalTrials.gov. NCT03473301: A Phase I/II Study of Allogeneic Umbilical Cord Blood and Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Infusions in Children With Cerebral Palsy. https://clinicaltrials.gov/ct2/show/NCT03473301?term=kurtzberg&rank=3. Accessed June 13, 2019.
52. ClinicalTrials.gov. NCT02881970: Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells (NEOSTEM). https://clinicaltrials.gov/ct2/show/NCT02881970. Accessed June 21, 2019.
53. ClinicalTrials.gov. NCT03826498: Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy. https://clinicaltrials.gov/ct2/show/NCT03826498. Accessed December 7, 2020.
54. ClinicalTrials.gov. NCT03431480: Safety Study of Autologous Cord Blood Stem Cell Treatment in Hypoplastic Left Heart Syndrome Patients Undergoing the Norwood Heart Operation. https://clinicaltrials.gov/ct2/show/NCT03431480. Accessed December 7, 2020.
55. ClinicalTrials.gov. NCT01883076: Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome. https://clinicaltrials.gov/ct2/show/NCT01883076. Accessed December 7, 2020.
56. ClinicalTrials.gov. NCT03779711: Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2). https://clinicaltrials.gov/ct2/show/NCT03779711. Accessed June 21, 2019.
57. ClinicalTrials.gov. NCT03558269: Pilot Study to Assess the Efficacy of Autologous Umbilical Cord Blood Treatment of Brain and Heart Injury in Neonates With Congenital Heart Defect. https://clinicaltrials.gov/ct2/show/NCT03558269. Accessed December 7, 2020.
58. ClinicalTrials.gov. NCT03855202: The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms. https://clinicaltrials.gov/ct2/show/NCT03855202. Accessed December 7, 2020.
59. ClinicalTrials.gov. NCT01897987: Follow-up Safety and Efficacy Evaluation on Subjects Who Completed the Initial Stage of PNEUMOSTEM® Phase-II Clinical Trial. [Completed]. https://clinicaltrials.gov/ct2/show/NCT01897987. Accessed December 7, 2020.
60. ClinicalTrials.gov. NCT01632475: Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia. https://clinicaltrials.gov/ct2/show/NCT01632475. Accessed June 21, 2019.
61. ClinicalTrials.gov. NCT03378063: Stem Cells for Bronchopulmonary Dysplasia: a Cohort Study. https://clinicaltrials.gov/ct2/show/NCT03378063?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=124. Accessed December 7, 2020.
62. ClinicalTrials.gov. NCT02932826: Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells on Autoimmune Diabetes. https://clinicaltrials.gov/ct2/show/NCT02932826. Accessed December 7, 2020.
63. ClinicalTrials.gov. NCT03835312: Sequential Transplantation of Umbilical Cord Blood Stem Cells and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency Type 1 Diabetes Mellitus. https://clinicaltrials.gov/ct2/show/NCT03835312. Accessed December 7, 2020.
64. ClinicalTrials.gov. NCT03011021: Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells With Liraglutide on Autoimmune Diabetes. https://clinicaltrials.gov/ct2/show/NCT03011021. Accessed December 7, 2020.
65. ClinicalTrials.gov. NCT03269773: A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis. [Completed]. https://clinicaltrials.gov/ct2/show/NCT03269773?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=141. Accessed December 7, 2020.
66. ClinicalTrials.gov. NCT02926300: Extension Study, An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trials to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn’s Disease. https://clinicaltrials.gov/ct2/show/NCT02926300?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=142. Accessed December 7, 2020.
67. ClinicalTrials.gov. NCT02918123: Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis. https://clinicaltrials.gov/ct2/show/NCT02918123?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=143. Accessed December 7, 2020.
68. ClinicalTrials.gov. NCT03618784: A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis. https://clinicaltrials.gov/ct2/show/NCT03618784?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=131. Accessed December 7, 2020.
69. ClinicalTrials.gov. NCT02254863: Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells. https://clinicaltrials.gov/ct2/show/NCT02254863. Accessed June 21, 2019.
70. ClinicalTrials.gov. NCT03084861: A Multicenter, Randomized, Open-label, Two-arms Phase I/II Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy. https://clinicaltrials.gov/ct2/show/NCT03084861. Accessed June 21, 2019.
71. ClinicalTrials.gov. Search Results 06/14/2019: Keywords: „umbilical cord“ AND „mesenchymal stem cells“; Filters: Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies. 2019. https://clinicaltrials.gov/ct2/results?term=%22umbilical+cord%22%2C+%22mesenchymal+stem+cells%22&flds=
abdefgikpy&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply. Accessed June 14, 2019.
72. ClinicalTrials.gov. Search Results 06/14/2019: Keywords: „umbilical cord“ AND „mesenchymal stem cells“; Filters: Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies; Phase 2. 2019. https://clinicaltrials.gov/ct2/results?term=%22umbilical+cord%22%2C+%22mesenchymal+stem+cells%22&recrs=b&recrs=a&recrs=
f&recrs=d&age_v=&gndr=&type=&rslt=&phase=1&Search=Apply. Accessed June 14, 2019.
73. ClinicalTrials.gov. NCT03521323: The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Early Stage of Chronic Spinal Cord Injury：A Multicenter, Randomized, Controlled Trial. https://clinicaltrials.gov/ct2/show/NCT03521323. Accessed March 15, 2021.
74. ClinicalTrials.gov. NCT03505034: The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Late Stage of Chronic Spinal Cord Injury：A Multicenter, Prospective, Cohort Study. https://clinicaltrials.gov/ct2/show/NCT03505034. Accessed March 15, 2021.
75. ClinicalTrials.gov. NCT03521336: The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Sub-Acute Spinal Cord Injury：A Multicenter, Randomized, Controlled Trial. https://clinicaltrials.gov/ct2/show/NCT03521336. Accessed March 15, 2021.
76. ClinicalTrials.gov. NCT04314687: Allogeneic Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium for Cerebral Palsy in Children. https://clinicaltrials.gov/ct2/show/NCT04314687. Accessed March 15, 2021.
77. ClinicalTrials.gov. NCT03383081: A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis. https://clinicaltrials.gov/ct2/show/NCT03383081. Accessed March 15, 2021.
78. ClinicalTrials.gov. NCT03818737: Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (SVF), and Third-party Human Mesenchymal Stem Cells Manufactured From Umbilical Cord Tissue for the Treatment of Unilateral Knee Osteoarthritis (OA). https://clinicaltrials.gov/ct2/show/NCT03818737. Accessed December 7, 2020.
79. ClinicalTrials.gov. NCT04011059: Randomized Study as Proof of Concept of Coronary Revascularization Surgery With Injection of Wharton’s Jelly-derived Mesenchymal Cells and Placement of an Epicardial Extracellular Matrix Patch Seeded With WJ-MSCs in Patients With Ischemic Cardiomyopathy. https://clinicaltrials.gov/ct2/show/NCT04011059. Accessed March 15, 2021.
80. ClinicalTrials.gov. NCT03765957: Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells. https://clinicaltrials.gov/ct2/show/NCT03765957. Accessed March 15, 2021.
81. ClinicalTrials.gov. NCT03562065: Treatment of Refractory Systemic Lupus Erythematosus by Injection of Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord. https://clinicaltrials.gov/ct2/show/NCT03562065. Accessed March 15, 2021.
82. ClinicalTrials.gov. NCT03580291: A Randomized, Double-Blind, Parallel-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in Patients With Lupus Nephritis. https://clinicaltrials.gov/ct2/show/NCT03580291. Accessed July 29, 2019.
83. Bing Liang, Junhui Chen, Tao Li, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. http://chinaxiv.org/abs/202002.00084. Updated February 27, 2020.
84. Atluri S;Manchikanti L;Hirsch J.A. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain Physician. 2020;23(2):E71-E83.
85. Assistance Publique – Hôpitaux de Paris. NCT04333368: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS. https://clinicaltrials.gov/ct2/show/NCT04333368. Updated April 22, 2020. Accessed April 22, 2020.
86. ClinicalTrials.gov. Liste laufender Studien zur Anwendung von MSCs aus Nabelschnurgewebe zur Behandlung von COVID-19-Lungenentzündung, Teil-1. https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=&intr=UC-MSC&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f. Accessed March 11, 2021.
87. ClinicalTrials.gov. Liste laufender Studien zur Anwendung von MSCs aus Nabelschnurgewebe zur Behandlung von COVID-19-Lungenentzündung, Teil-2. https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=&intr=WJ-MSC&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f. Accessed March 11, 2021.